[PDF]Generic Rx Projected New Generic Releases - Rackcdn.comec136126026ae0ee21c6-6b9280afdddbd69575967dcab27a2354.r32.cf2.rackcdn.co...
2 downloads
181 Views
658KB Size
COMING SOON!
Generic Rx
Helping you effectively manage your inventory
Projected New Generic Releases
Page 1 of 2 Dosage Form
Earliest Possible Generic Launch Date*
Injection
3/2/13
Pain Management
Tablets
5/14/13
Zolmitriptan
Pain Management
Tablets
5/14/13
Rilutek®
Riluzole
ALS
Tablets
6/18/13
Temodar® (capsules)
Temozolomide
Oncology
Capsules
8/11/13
Cellcept® (Intravenous)
Mycophenolate Mofetil
Prophylaxis of Organ Rejection
Injection
9/15/13
Lidoderm®
Lidocaine
Pain Management
Patch
9/15/13
Advicor®
Lovastatin, Niacin
Cardiovascular
Tablets
9/20/13
Niaspan®
Niacin
Cardiovascular
Tablets
9/20/13
Aciphex®
Rabeprazole Sodium
Gastrointestinal
Tablets
11/8/13
Cymbalta®
Duloxetine Hydrochloride
CNS
Capsules
12/11/13
Vanos®
Fluocinonide
Dermatology
Cream
12/15/13
Locoid Lipocream®
Hydrocortisone Butyrate
Dermatology
Cream
Q4 2013
Aplenzin® (348mg)
Bupropion Hydrobromide
CNS
Tablets
Q4 2013
Astepro® (0.15%)
Azelastine Hydrochloride
Respiratory
Nasal Spray
Pending a Settlement Agreement
Clarinex-D® 24 Hour
Desloratadine, Psuedoephedrine sulfate
Respiratory
Tablets
Pending a Settlement Agreement
Adenoscan®
Adenosine
Cardiovascular
Injection
Pending FDA Approval
Atacand®
Candesartan cilexetil
Cardiovascular
Tablets
Pending FDA Approval
Diovan®
Valsartan
High Blood Pressure
Tablets
Pending FDA Approval
Lescol® XL
Fluvastatin Sodium
Cholesteral Lowering
ER Tablets
Pending FDA Approval
Vidaza®
Azacitidine
Oncology
Injection
Pending FDA Approval
Brand Name
Generic Name
Indication
Reclast®
Zoledronic acid
Metabolic Disorders
Zomig® (tablets)
Zolmitriptan
Zomig-ZMT®
Pending Litigation/FDA Approval
*NOTE: Product release dates are influenced by evolving market conditions, legal actions and other factors. Launch dates are anticipated, but not guaranteed. The products on this list are those for which the probability of a generic being approved and launched are almost certain. There are other products that could launch during this time frame, but due to uncertainties, they are not included. For full prescribing information, please see manufacturer’s package insert.
If you do not wish to receive future fax notifications, or have received this in error, please call 866.481.9644.
March 2013
Day 181 Alert
Generic Rx
Helping you effectively manage your inventory
Exclusivity End Date Alerts
Page 2 of 2
These generic items will lose exclusivity in the near future. As a result, pricing in the market will likely decrease at that time. Use this alert as a reminder to manage your inventory accordingly. Brand Name
Generic Name
FazaClo® ODT
Clozapine ODT
Diovan HCT®
Valsartan and Hydrochlorothiazide
Launch Date 9/4/12
End Date Early March 2013
9/24/12
Late March 2013
Metadate CD®
Methylphenidate HCl CD
9/28/12
Late March 2013
Comtan®
Entacapone
10/3/12
Early April 2013
Gabitril® (2,4 mg only)
Tiagabine HCL
10/19/12
Mid April 2013
Atacand HCT® (32-25mg only)
Candesartan Cilexetil HCTZ (32-25mg only)
12/5/12
Early June 2013
Propecia®
Finasteride
1/3/13
Late June 2013
Maxalt MLT®
Rizatriptan Benzoate ODT
1/3/13
Late June 2013
Lysteda®
Tranexamic Acid
1/7/13
Early July 2013
Duetact®
Pioglitazone HCl/Glimepiride
1/9/13
Early July 2013
Opana ER®
Oxymorphone HCI ER
2/5/13
Early July 2013
NOTE: Dates subject to change
If you do not wish to receive future fax notifications, or have received this in error, please call 866.481.9644.
March 2013